0001209191-20-007525.txt : 20200207
0001209191-20-007525.hdr.sgml : 20200207
20200207162847
ACCESSION NUMBER: 0001209191-20-007525
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tatsis Ourania
CENTRAL INDEX KEY: 0001789815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20587854
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-05
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001789815
Tatsis Ourania
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
SVP, CRO
Common Stock
2020-02-05
4
A
0
3500
0.00
A
10752
D
Common Stock
2020-02-05
4
A
0
6194
0.00
A
16946
D
Common Stock
2020-02-06
4
M
0
559
187.53
A
17505
D
Common Stock
2020-02-06
4
M
0
408
155.57
A
17913
D
Common Stock
2020-02-06
4
S
0
571
238.77
D
17342
D
Common Stock
2020-02-06
4
S
0
240
239.68
D
17102
D
Common Stock
2020-02-06
4
S
0
90
240.70
D
17012
D
Common Stock
2020-02-06
4
S
0
66
242.47
D
16946
D
Stock Option (Right to Buy)
187.53
2020-02-06
4
M
0
559
0.00
D
2029-02-05
Common Stock
559
6704
D
Stock Option (Right to Buy)
155.57
2020-02-06
4
M
0
408
0.00
D
2028-02-05
Common Stock
408
3261
D
Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020.
Restricted stock unit award that vests in installments beginning on 02/10/2021.
Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $238.77 (range $238.20 to $239.14).
Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $239.68 (range $239.25 to $240.13).
Open market sales reported on this line occurred at a weighted average price of $240.70 (range $240.47 to $241.04).
The option vests in 16 quarterly installments from 02/06/2019.
The option vests in 16 quarterly installments from 02/06/2018.
/s/ Omar White, Attorney-in-Fact
2020-02-07